Hepion Pharmaceuticals, Inc. financial data

Symbol
HEPA, CTRVP on OTC
Location
Edison, NJ
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 12 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 811% % 193%
Debt-to-equity 29% % -85%
Return On Equity -242% % 56%
Return On Assets -188% % 2.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 11,620,317 shares 5.9%
Common Stock, Shares, Outstanding 11,620,317 shares 8250%
Entity Public Float $900,000 USD -85%
Common Stock, Value, Issued $1,162 USD 8200%
Weighted Average Number of Shares Outstanding, Basic 9,409,375 shares 7556%
Weighted Average Number of Shares Outstanding, Diluted 9,409,375 shares 7556%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $2,616,613 USD -89%
General and Administrative Expense $3,315,433 USD -56%
Operating Income (Loss) $4,163,691 USD 78%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $8,277,850 USD 49%
Income Tax Expense (Benefit) $3,378,274 USD -17%
Net Income (Loss) Attributable to Parent $8,277,850 USD 37%
Earnings Per Share, Basic -0.88 USD/shares 99%
Earnings Per Share, Diluted -0.88 USD/shares 99%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $3,069,952 USD 90%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $0 USD
Other Assets, Noncurrent $66,505 USD
Assets $3,069,952 USD 90%
Accounts Payable, Current $167,810 USD -24%
Accrued Liabilities, Current $77,507 USD 227%
Liabilities, Current $299,383 USD -90%
Operating Lease, Liability, Noncurrent $41,248 USD
Liabilities $402,405 USD -88%
Accumulated Other Comprehensive Income (Loss), Net of Tax $8,345 USD 0%
Retained Earnings (Accumulated Deficit) $246,097,656 USD -3.5%
Stockholders' Equity Attributable to Parent $2,667,547 USD
Liabilities and Equity $3,069,952 USD 90%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,117,422 USD 69%
Net Cash Provided by (Used in) Financing Activities $5,297,403 USD 186%
Net Cash Provided by (Used in) Investing Activities $0 USD
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 11,620,317 shares 8250%
Common Stock, Par or Stated Value Per Share 0.0001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $4,179,981 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,828,062 USD 350%
Deferred Tax Assets, Valuation Allowance $45,489,265 USD 2%
Deferred Tax Assets, Gross $45,489,265 USD 2%
Operating Lease, Liability $0 USD
Depreciation $100,000 USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $8,277,850 USD 37%
Lessee, Operating Lease, Liability, to be Paid $139,259 USD -47%
Operating Lease, Liability, Current $117,952 USD 5%
Lessee, Operating Lease, Liability, to be Paid, Year One $97,815 USD -29%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $21,307 USD 3%
Additional Paid in Capital $247,060,568 USD 5.5%
Current State and Local Tax Expense (Benefit) $3,000,000 USD
Depreciation, Depletion and Amortization $30,758 USD 71%
Share-based Payment Arrangement, Expense $106,658 USD -91%
Interest Expense $11,492 USD 12%